Is This Heavily Shorted Biotech Stock a Good Contrarian Buy?
Short-sellers have piled into Adaptimmune Therapeutics and MannKind Corp. this year. Could these two biotechs represent good contrarian buys for the long-term investor?
Stocks To Watch in Orphan Drugs
Acceleron Pharma, bluebird bio, and Sarepta Therapeutics are three rare disease specialists with upcoming catalysts that could propel their shares higher.